Of particular interest, high PEAK1 expression occurs in triple negative breast cancer (TNBC) and pancreatic cancer6,10, two cancers associated with poor prognosis and limited targeted therapeutic options. This evidence concerns the gene PEAK1 and triple-negative breast carcinoma.